Abstract:Background: Long-term observations and studies have found that the occurrence and development of lung adenocarcinoma (LUAD) is associated with certain metabolic changes and that metabolic disorders are directly related to carcinogenic gene mutations. We attempted to establish a prognostic model for LUAD based on the expression profiles of metabolic genes. Method: We analyzed the gene expression profiles of patients with LUAD obtained from The Cancer Genome Atlas (TCGA). Univariate Cox regression was used to assess the correlation between each metabolic gene and survival. The survival-related metabolic genes were fit into the least absolute shrinkage and selection operator (LASSO) to establish a prognostic model for LUAD. After 100,000 times of calculations and model construction, we successfully established a prognostic model consisting of 16 genes that can classify patients with LUAD into high-risk and low-risk groups. Further, the protein-protein interaction (PPI) network was built to determine the hub gene from16 metabolic genes. Finally, the top one hub gene was validated by real-time reverse transcription quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry in our 50 paired LUAD and adjacent tissues, and the prognostic performance of 16 metabolic genes was validated in GEO LUAD cohorts. Results: Univariate Cox regression analysis and LASSO regression analysis results showed that the prognostic model established based on 16 metabolic genes could differentiate patients with LUAD with significantly different overall survival (OS) and that the prognosis of the high-risk group was worse than that of the low-risk group. In addition, the model can independently predict the OS of patients in both the training cohort and the validation cohort (training cohort: HR =2.44, 95% CI: 1.58-3.74, P<0.05; validation cohort: HR = 2.15, 95% CI: 2.52-2.70, P<0.05). The decision curve analysis further showed that the combination use of the prognostic model and clinical features could better predict the survival of patients and benefit patients. In addition, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses revealed several basic signaling pathways and biological processes of metabolic genes in LUAD. Combined with the clinical features and metabolic gene characteristics of patients with LUAD, we also constructed a survival nomogram with a C-index of 0.701 to predict the survival probability of patients. The calibration curve confirmed that the nomogram predications were consistent with the actual observation results. The top one hub gene was TYMS, which was determined by PPI. TYMS levels in LUAD were detected by RT-qPCR and the expression of TYMS was significantly up-regulated in the LUAD tissue of all 50 pairs (t=11.079, P<0.0001). Simultaneously, the correct of the prognostic model was validated, based on the data in GSE37745. Conclusions: We constructed and validated a new prognostic model based on metabolic genes. This model could provide guidance for the personalized treatment of patients and improve the accuracy of individualized prognoses for patients with LUAD.

Predicting lung adenocarcinoma prognosis, immune escape, and pharmacomic profile from arginine and proline-related genes

Development and Validation of Polyamines Metabolism-Associated Gene Signatures to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma.

A Model of Twenty-Three Metabolic-Related Genes Predicting Overall Survival for Lung Adenocarcinoma

Construction of a Lung Adenocarcinoma Prognostic Model Utilizing Serine and Glycine Metabolism-Related Genes

Identification and Verification of Metabolism-related Immunotherapy Features and Prognosis in Lung Adenocarcinoma

Identification and Validation of a Novel Apoptosis-Related Prognostic Risk Score Model for Lung Adenocarcinoma

Construction of a Prognostic Model for Lung Adenocarcinoma Based on Bioinformatics Analysis of Metabolic Genes

The prognostic and clinical value of genes associate with immunity and amino acid Metabolism in Lung Adenocarcinoma

Comprehensive analyses of one-carbon metabolism related genes and their association with prognosis, tumor microenvironment, chemotherapy resistance and immunotherapy in lung adenocarcinoma

SLC2A1 Plays a Significant Prognostic Role in Lung Adenocarcinoma and is Associated with Tumor Immunity Based on Bioinformatics Analysis.

Characterization of Polyamine Metabolism Predicts Prognosis, Immune Profile, and Therapeutic Efficacy in Lung Adenocarcinoma Patients

Identification of Metabolism-Related Gene Signature in Lung Adenocarcinoma

Establishment and validation of a prognostic signature for lung adenocarcinoma based on metabolism‐related genes

Liquid-Liquid Phase Separation in the Prognosis of Lung Adenocarcinoma: An Integrated Analysis

Anoikis-related subtype and prognosis analyses based on bioinformatics, and an expression verification of ANGPTL4 based on experiments of lung adenocarcinoma

Identification of a Five Autophagy Subtype-Related Gene Expression Pattern for Improving the Prognosis of Lung Adenocarcinoma

Identifying a lactic acid metabolism-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma

Prognostic Value of Metabolic Genes in Lung Adenocarcinoma Via Integrative Analyses.

Development of a prognostic model for lung adenocarcinoma polarity‐related genes and analysis of immune landscape

Comprehensive Analysis of Immune-Related Metabolic Genes in Lung Adenocarcinoma

Integration of Bulk RNA Sequencing to Reveal Protein Arginine Methylation Regulators Have a Good Prognostic Value in Immunotherapy to Treat Lung Adenocarcinoma